

# New Methodology for the Development of Chromatographic Methods

E. Rozet, B. Debrus, P. Lebrun, B. Boulanger, Ph. Hubert



**17<sup>th</sup> International Symposium on Separation Sciences**

*News and Beauty in Separation Sciences*

*September 5-9, 2011 - Grand Hotel Napoca - Cluj-Napoca, Romania*

## Outline

### 1. Introduction

### 2. The methodology

- 2.1. Designs of Experiments and modeling
- 2.2. Error propagation and DS
- 2.3. Automatic reading of chromatograms

### 3. Application of the methodology

- 3.1. Mixture of 9 compounds
- 3.2. Improvement of Eur Ph Monography
- 3.3. Antimalarial compounds
- 3.4. Application to Legal Toxicology Sciences
- 3.5. Chiral separation

### 4. Conclusions


# 1. Introduction

- Rapid development of methods using commercially available products.

- DryLab®
- Chromsword®

- ACD/LC simulator®
- Osiris®

**Chromatographic Theory:**  
→ Prediction of  $R_s$



**What probability of success?**

3

# 1. Introduction

## Regulatory requirement

### International Conference on Harmonization (ICH)


- ICH Q8(R2): Pharmaceutical development

→ Quality by Design (QbD)

→ Design Space (DS)

"the *multidimensional combination and interaction of input variables and process parameters that have been demonstrated to provide assurance of quality.*"

→ DS is a sub-region of the experimental domain in which the objectives are reached with a defined probability.



4

# 1. Introduction

## Regulatory requirement

### International Conference on Harmonization (ICH)

• ICH Q8(R2): Pharmaceutical development

→ Quality by Design (QbD)

→ Design Space (DS)

"working within the **DS** is not considered as a change."



### *ICH Q2(R1): Analytical method validation*

"The **robustness** of an analytical procedure is a measure of its capacity to remain unaffected by small, but **deliberate variations in method parameters** and provides an indication of its reliability during normal usage."

5

## Outline

### 1. Introduction

### 2. The methodology

2.1. Designs of Experiments and modeling

2.2. Error propagation

2.3. Automatic reading of chromatograms

### 3. Application of the methodology

3.1. Mixture of 9 compounds

3.2. Pharmaceutical formulation

3.3. Improvement of EurPh Monography

3.4. Application to Legal Toxicology Sciences


3.5. Chiral separation

### 4. Conclusions

6

## 2.1. DoEs and Modeling

Model chromatographic behaviour through **Design of Experiments (DoEs)**.



$$Y = \beta_0 + \beta_1 \times X_1 + \beta_2 \times X_2 + \dots + \epsilon$$



response                      factors                      error

7

## 2.1. DoEs and Modeling

Selection of a response

Selection of factors




8

## 2.1. DoEs and Modeling

Selection of a response


$$t_R = f(X)$$



Selection of factors


Factors having most effect:

- Stationary phase
- Organic modifier
- pH
- Gradient time
- Temperature
- ...



9

## 2.1. DoEs and Modeling



Modeled Responses

- $\log(k)$   $k = (t_R - t_0)/t_0$
- $\log(\omega_{/2 \text{ left}})$
- $\log(\omega_{/2 \text{ right}})$

Mathematical Models

(multiple linear equation)


e.g. gradient time ( $t_G$ ) and pH

$$\log(k) = \beta_0 + \beta_1 \cdot t_G + \beta_3 \cdot t_G^2 + \beta_4 \cdot \text{pH} + \beta_5 \cdot \text{pH}^2 + \beta_6 \cdot \text{pH}^3 + \beta_7 \cdot \text{pH}^4 + \beta_8 \cdot t_G \cdot \text{pH} + \varepsilon$$

Optimised criteria

- $R_S$
- $S = t_{R, \text{begin}} - t_{R, \text{end}}$
- Analysis time


## 2.2. Error propagation and DS



P. Lebrun et al., Chemom. Intell. Lab. Syst. 91 (2008) 4.


11

## 2.2. Error propagation and DS



12

## 2.2. Error propagation and DS



P. Lebrun et al., Chemom. Intell. Lab. Syst. 91 (2008) 4.


13

## 2.2. Error propagation and DS

The design space  $\rightarrow$  region of probability of success

$$DS = \{x_0 \in \chi | E_{\hat{\theta}} [P(S > \lambda) | \hat{\theta}] \geq \pi\}$$

$$\hat{\theta} = (\beta_1, \dots, \beta_{10}, \varepsilon)$$





P. Lebrun et al., Chemom. Intell. Lab. Syst. 91 (2008) 4.

14

## 2.3. Automatic reading


### Problem stating



15

## 2.3. ICA in liquid chromatography

### Independent Component Analysis (ICA)




16



## 2.3. ICA in liquid chromatography

ICA (nbr of sources = 12)




200 nm – 400 nm → 240 nm

B. Debrus, et al., Talanta 79 (2009) 77.


17

## 2.3. ICA in liquid chromatography

Asymetrical distribution  
Non gaussian



Gaussian distribution




B. Debrus, et al., Talanta 79 (2009) 77.

18


## 2.3. ICA in liquid chromatography

### Kurtosis



Kurtosis > 3 Over-normal (leptokurtic)  
Kurtosis = 3 Normal Distribution (mesokurtic)  
Kurtosis < 3 Sub-normal (platikurtic)


### Shapiro-Wilk Test




$W_{S-W} = 1 > p_{S-W} > p_{S-W}$   
↓  
Normal Distribution

19

## 2.3. ICA in liquid chromatography




## 2.3. ICA in liquid chromatography




21

## 2.3. ICA in liquid chromatography



B. Debrus, et al., Talanta 79 (2009) 77.

## 2.3. ICA in liquid chromatography




B. Debrus, et al., Talanta 79 (2009) 77.  $n$

23

## 2.3. ICA in liquid chromatography


Mixture of 4 compounds

24 experimental conditions  
 $\rightarrow$  26 chromatograms



Mixture of 9 compounds


15 experimental conditions  
 $\rightarrow$  17 chromatograms



B. Debrus, et al., Talanta 79 (2009) 77.

24

## DoE-ICA-DS methodology



25

## Outline

### 1. Introduction

### 2. The methodology

- 2.1. Designs of Experiments and modeling
- 2.2. Error propagation
- 2.3. Automatic reading of chromatograms

### 3. Application of the methodology


- 3.1. Mixture of 9 compounds
- 3.2. Improvement of EurPh Monography
- 3.3. Antimalarial compounds
- 3.4. Application to Legal Toxicology Sciences
- 3.5. Chiral separation

### 4. Conclusions

26


## 3.1. Application - 1

### 1. Mixture of 9 unknown compounds



XBridge C18  
100 × 2.1 mm  
3.5  $\mu$ m

B. Debrus, et al., Anal. Chim. Acta 691 (2011) 33



27


## 3.1. Application - 1

Normality test  
of Shapiro-Wilk

p-value = 0.111

p-value = 0.129

p-value = 0.080




Atenolol Naproxen  
Pindolol Warfarin  
Unknown RA-Imp  
Propranolol Retinoic Acid

B. Debrus, et al., Anal. Chim. Acta 691 (2011) 33

28


## 3.1. Application - 1



B. Debrus, et al., Anal. Chim. Acta 691 (2011) 33

29


## 3.1. Application - 1



B. Debrus, et al., Anal. Chim. Acta 691 (2011) 33

30

## 3.1. Application - 1



31

## 3.2. Application - 2

### 2. Antimalarial compounds

19 antimalarial drugs	
chloroquine	proguanil
amodiaquine	mefloquine
sulfalene	Lumefantrine
sulfadoxine	Atovaquone
cinchonine	Piperaquine
quinine	Artesunate
pyriméthamine	Arteether
primaquine	Artemether
halofantrine	Artemisinin
dihydroartemisinin	

### Full Factorial Design

pH	$t_G$ (min)	T (°C)
2.5	20	25
4	40	30
6	60	35
8		

Precolumn  
XBridge C18  
20 × 4.6 mm  
5  $\mu$ m

Column  
XBridge C18  
250 × 4.6 mm  
5  $\mu$ m




B. Debrus, et al., J. Chromatogr. A, 1218 (2011) 5205

32



## 3.2. Application - 2




33


## 3.2. Application - 2

Mixture of 18 molecules

DS ( $\pi$  = 28%)




Optimal condition: pH 4.05 –  $t_G$  = 56.2 min –  $T$  = 25 °C



34

## 3.2. Application - 2

Mixture 1	Mixture 2	Mixture 3	Mixture 4	Mixture 5
Amodiaquine Artesunate	Sulfalene Pyrimethamine Artesunate	Artemether Lumefantrine	Sulfalene Pyrimethamine Dihydroartemisinin	Piperaquine Dihydroartemisinin




B. Debrus, et al., J. Chromatogr. A, 1218 (2011) 5205

35

## 3.2. Application - 2


Mixture 1	Mixture 2	Mixture 3	Mixture 4	Mixture 5
Amodiaquine Artésunate	Sulfalène Pyriméthamine Artésunate	Arteméthér Luméfántrine	Sulfalène Pyriméthamine Dihydroartemisinine	Pipéraquine Dihydroartemisinine



B. Debrus, et al., J. Chromatogr. A, 1218 (2011) 5205

36

## 3.2. Application - 2



Mix.	Compound	$t_R$ pred.	$t_R$ observed	error
1	Amodiaquine	13,51	13,85	-0,34
	Artésunate	19,10	19,26	-0,16
2	Sulfalène	11,23	10,83	0,40
	Pyriméthamine	16,27	16,60	-0,33
3	Artésunate	19,26	19,37	-0,11
	Artéméther	23,09	23,17	-0,08
4	Luméfantine	25,99	26,90	-0,91
	Sulfalène	11,29	10,97	0,32
5	Pyriméthamine	15,45	15,42	0,03
	Dihydroartémisinine	20,00	20,11	-0,11
5	Piéprouquine	7,45	8,14	-0,69
	Dihydroartémisinine	20,08	20,12	-0,04
Mean  error				0,29

B. Debrus, et al., J. Chromatogr. A, 1218 (2011) 5205

37

## 3.3. Application - 3

### 3. Eur Ph. Monography


#### Full factorial design

#### 4 compounds:

- sulindac (sulfoxide – Z isomer)
- sulfone
- sulfide
- E-sulindac

Rocket Platinum C18  
53 mm × 7 mm, 1.5  $\mu$ m


Factors	Levels		
$T_P$ (min)	0	1	
pcl (%)	15	30	45
$T_G$ (min)	1	3	5
pcF (%)	55	60	65



F. Krier et al., J. Pharm. Biomed. Anal. 54 (2011) 694.

38

### 3.3. Application - 3



F. Krier et al., J. Pharm. Biomed. Anal. 54 (2011) 694.

39

### 3.4. Application - 4

#### 4. Legal Toxicology


##### 9 compounds:

Prazepam (IS)  
 CBDA, CBGA  
 CBD, CBG  
 THCA, d9-THC, d8-THC  
 CBN

##### Full factorial design

Factors	Levels				
pH	2.6	4.45	6.3	8.15	10
$T_G$ (min, $\%_{ini} \rightarrow 95\%$ )	10	20	30		
$\%_{ini}$ (MeOH)	5	40	75		



XBridge C18 150 mm  $\times$  4.6mm, 5 $\mu$ m



De Backer et al., J. Chromatogr. B 877 (2009) 4115.

40

## 3.4. Application - 4



De Backer et al., J. Chromatogr. B 877 (2009) 4115.

41

## 3.5. Application - 5

### 5. Chiral Separation

1 basic compound  
2 chiral centers

#### Central Composite design

Factors	Levels	
%TFA	0.05	0.15
%n-hexan	1	10
t°C	10	25

Chiral selector:

cellulose tris(4-chloro-3-methylphenylcarbamate)

DEA 0.1%

42

## 3.5. Application - 5


Work still in progress

### Optimal conditions:

8.65% n-hexane,

13°C,

0.08% TFA




43

## Conclusions

- The proposed methodology allows modeling the chromatographic behaviour of the studied compounds.
- It allows to propagate prediction uncertainty and thus allows to define the *design space* and is compliant with the concept of *Quality by Design (QbD)*.
- ICA allows the separation of coeluted peaks and the automatic reading of chromatograms (detection and indexing peaks).
- The global methodology DoE-ICA-DS has demonstrated its capacity to allow the development of chromatographic methods that are optimal and robust.
- Not limited to chromatography, nor to analytical chemistry ... any process


44

## DoE-ICA-DS methodology



45

## Acknowledgments



Prof. Ph. Hubert  
**Dr. B. Debrus**  
 Dr. A. Ceccato  
**P. Lebrun**  
 F. Lecomte  
 Prof. C. Charlier  
 B. De Backer  
 N. Dubois

Prof. C. Barbas (Madrid)  
 Prof. J.-L. Veuthey (Genève)  
 Prof. S. Rudaz (Genève)  
 Dr. D. Guillarme (Genève)  
 Prof. P. Esseiva (Lausanne)  
 Prof. J. Quetin-Leclercq (UCL)

FRS-FNRS  
 Région Wallonne  
 Eli Lilly  
 Arlenda

46

# Thank you for your attention

---

- Check our publications at:

<http://orbi.ulg.ac.be/>



- Contact:

[Eric.Rozet@ulg.ac.be](mailto:Eric.Rozet@ulg.ac.be)



**17<sup>th</sup> International Symposium on Separation Sciences**

*News and Beauty in Separation Sciences*

*September 5-9, 2011 - Grand Hotel Napoca - Cluj-Napoca, Romania*



UNIVERSITY of LIEGE